Apimeds Pharmaceuticals US Inc (APUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | |
| Assets | |||
| Current Assets | |||
| Cash & Cash Equivalents | 9,637 | 4 | 411 |
| Marketable Securities | 2,000 | N/A | N/A |
| Other current assets | 49 | 0 | 0 |
| TOTAL | $13,984 | $13 | $422 |
| Non-Current Assets | |||
| PPE Net | 52 | N/A | N/A |
| Intangibles | 149,885 | 0 | 0 |
| Other Non-Current Assets | 263 | 0 | 0 |
| TOTAL | $150,200 | $N/A | $N/A |
| Total Assets | $164,184 | $13 | $422 |
| Liabilities | |||
| Current Liabilities | |||
| Short Term Debt | 7,091 | N/A | N/A |
| Accounts payable and accrued liabilities | 931 | 668 | 54 |
| Accrued Expenses | 528 | 107 | 69 |
| Other current liabilities | 1,617 | N/A | N/A |
| TOTAL | $10,707 | $1,024 | $123 |
| Non-Current Liabilities | |||
| Other Non-Current Liabilities | 130 | 347 | 267 |
| TOTAL | $130 | $347 | $267 |
| Total Liabilities | $10,836 | $1,371 | $390 |
| Shareholders' Equity | |||
| Shares Outstanding, K | 12,576 | N/A | N/A |
| Common Shares | 126 | 79 | 79 |
| Retained earnings | -10,393 | -4,392 | -3,002 |
| TOTAL | $153,348 | $-1,358 | $32 |
| Total Liabilities And Equity | $164,184 | $13 | $422 |